FC2ブログ

バイオの戯言

ライフサイエンスに関する話題についてコメント(戯言?)を述べていくブログです。

【プレスリリースメモ】 RNAi関係 (2013.5.11)  

<Alnylam Pharmaceuticals>
Alnylam Pharmaceuticals Reports First Quarter 2013 Financial Results(2013.5.6)
Alnylam to Webcast Presentation at 2013 Bank of America Merrill Lynch Health Care Conference(2013.5.8)

<Arrowhead Research>
Arrowhead Closes $36 Million Private Offering(2013.5.6)
Arrowhead Receives Patent Allowance for DPC siRNA Delivery System with Peptide Backbone(2013.5.7)
Arrowhead Reports Fiscal 2013 Second Quarter Financial Results(2013.5.9)

<CytRx Corporation>
CytRx Receives Recommendation from Data Safety Monitoring Committee to Complete International Phase 2b Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma(2013.5.6)
CytRx Provides Update on Clinical Programs(2013.5.8)
CytRx Reports 2013 First Quarter Financial Results(2013.5.9)

<Dynavax Technologies>
Dynavax Reports First Quarter 2013 Financial Results(2013.5.6)

<Exiqon A/S>
Exiqon A/S - INTERIM REPORT FOR THE PERIOD 1 JANUARY - 31 MARCH 2013 (UNAUDITED)(2013.5.6)

<Galena Biopharma>
VIDEO RELEASE -- Galena Biopharma Reports First Quarter 2013 Financial Results(2013.5.9)
Galena Biopharma Poster Presentation at the American Pain Society 32nd Annual Scientific Meeting(2013.5.9)

<iCo Therapeutics>
iCo Therapeutics Announces Overnight Marketed Equity Offering(2013.5.9)
iCo Therapeutics to Raise $3.2 Million(2013.5.10)

<Idera Pharmaceuticals>
Idera Pharmaceuticals Announces Closing of Common Share Offering(2013.5.7)
Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque Psoriasis(2013.5.8)

<Isis Pharmaceuticals>
Isis Pharmaceuticals Announces the Initiation of a Clinical Study of ISIS-STAT3 Rx in Patients with Liver Cancer(2013.5.6)
Isis Reports Financial Results and Highlights for First Quarter 2013(2013.5.7)
Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock(2013.5.7)
Isis Pharmaceuticals Prices Public Offering Of Common Stock(2013.5.8)
Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference(2013.5.9)
Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec(2013.5.9)

<OPKO Health>
OPKO Announces First Quarter 2013 Operating and Financial Highlights(2013.5.9)

<Regulus Therapeutics>
Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call(2013.5.7)

<Rosetta Genomics>
Rosetta Genomics microRNA-based Diagnostic Assays to be Showcased in an Industry Expert Theater Presentation at ASCO's 2013 Annual Meeting(2013.5.7)
Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories(2013.5.10)

<RXi Pharmaceuticals>
RXi Pharmaceuticals to Present at IBC’s 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference(2013.5.9)

<Sarepta Therapeutics>
Sarepta Therapeutics Initiates Dosing in Phase I Multiple Ascending Dose Study of Drug for Treatment of Marburg Virus(2013.5.7)
Sarepta Therapeutics Announces First Quarter 2013 Financial Results and Recent Corporate Developments(2013.5.9)
Sarepta Therapeutics to Present Company Overview at Upcoming Conferences(2013.5.10)

<Sylentis>
El alcalde de Tres Cantos y el concejal de Economía, Empleo y Comercio visitan las instalaciones de Sylentis(2013.5.8)

<Tekmira Pharmaceuticals>
Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program(2013.5.8)
Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter Financial Results(2013.5.9)

<Valeant Pharmaceuticals>
Valeant Pharmaceuticals International, Inc. Announces Additional Information Regarding Continuance Proposal(2013.5.10)

<Vical>
Vaxfectin® Enhances Preclinical Immune Responses to Baxter's Cell Culture-Derived Influenza Vaccines(2013.5.6)
Vical to Present at May Investor Conferences(2013.5.7)
Vical Reports First Quarter 2013 Financial Results and Progress in Key Development Programs(2013.5.9)

<アンジェスMG>
・リンパ浮腫を対象としたコラテジェン(HGF 遺伝子治療薬)のプロジェクトがNEDO のイノベーション実用化ベンチャー支援事業に採択(2013.5.7)
当社提携先であるVical 社のAllovectin(R)第III相臨床試験の進捗状況について(2013.5.10)

<日本新薬>
国産初のアンチセンス核酸医薬品としてデュシェンヌ型筋ジストロフィー治療剤の臨床試験開始(2013.5.9)


スポンサーサイト
[ 2013/05/11 23:18 ] プレスリリース | TB(0) | CM(0)
コメントの投稿













管理者にだけ表示を許可する
最新ニュース
お気に入り
カレンダー(月別)
07 ≪│2018/08│≫ 09
- - - 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31 -
特選品
特許関係の書籍-3
特許関係の書籍-2
特許関係の書籍-1
情報関係の書籍
月別アーカイブ
プロフィール

のぐひで

Author:のぐひで
FC2ブログへようこそ!